-
June 1, 2020
Aileron Therapeutics Announces Positive Interim Results from Phase 1b/2 Clinical Trial of ALRN-6924 for the Prevention of Topotecan-induced Toxicities During Treatment for Small Cell Lung Cancer
-
May 27, 2020
Aileron Therapeutics Announces Initiation of Expansion Cohort and First Patient Enrolled into Expansion Cohort of Phase 1b/2 Study of ALRN-6924 as a Chemoprotection Agent
-
May 11, 2020
Aileron Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update
-
April 22, 2020
Aileron Therapeutics Announces Plans to Release Interim Results from its Phase 1b/2 Myelopreservation Study in Mid-2020
-
March 30, 2020
Aileron Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results
-
December 18, 2019
Aileron Therapeutics Announces the Promotion of Richard J. Wanstall to Chief Financial Officer and Treasurer
-
November 7, 2019
Aileron Therapeutics Reports Third Quarter 2019 Results
-
October 31, 2019
Aileron Therapeutics to Report Third Quarter 2019 Financial Results on November 7th
-
October 29, 2019
Aileron Therapeutics Announces Positive Nonclinical Myelopreservation Results for ALRN-6924 at the 2019 AACR-NCI-EORTC Conference
-
October 21, 2019
Aileron to Present Nonclinical Myelopreservation Data for ALRN-6924 at the 2019 AACR-NCI-EORTC Conference on October 29th